Pharma 4.0
Driving the future of pharma manufacturing
Sekhar Surabhi, CEO & Founder, Caliber Technologies | Director, ISPE India Affiliate | Chair, ISPE Pharma 4.0, Community of Practice (CoP)
In this exclusive interview, Sekhar Surabhi shares his vision for accelerating digital transformation in the pharmaceutical industry. As a long-standing leader in quality and compliance automation, and a board member of ISPE India, Sekhar offers deep insights into the evolving Pharma 4.0 landscape, the challenges of implementation, and the roadmap for Indian pharma to stay globally competitive. This conversation is a must-read for industry professionals navigating the intersection of innovation, regulation, and quality excellence.
1. How would you define the current maturity level of Pharma 4.0 adoption across Indian pharmaceutical companies?
Pharma 4.0, adapted from Industry 4.0, is tailored to meet the stringent regulatory demands of the pharmaceutical industry to ensure patient safety, data integrity and traceability. In India, the adoption is currently in the early to evolving stages, but the momentum is promising.
While some large, export-oriented companies have initiated digital transformation programs, widespread adoption remains limited. Most Indian pharma firms are focused on compliance- driven digitisation rather than end-to-end integration of digital technologies. The maturity spectrum is uneven, with isolated pockets of adoption and innovation rather than industry-wide transformation.
That said, there’s a noticeable shift: across the board, irrespective of company size, leaders are increasingly contemplating digital transformation. This growing intent signals a positive change, even if full-scale execution is still a work-in-progress.
2. What are the foundational digital enablers that Indian pharma firms must invest in today to lay the groundwork for a successful Pharma 4.0 transition?
I would say, before making any leaps towards Pharma 4.0, companies must thoroughly assess their foundational elements. A critical starting point to get right is the quality management maturity, as championed by ISPE’s APQ (Advancing Pharmaceutical Quality Program). The framework, Asses > Aspire > Act > Advance, emphasises the importance of improving quality culture before embracing digital transformation.
Next is to digitise all data and digitalise all processes, eliminating silos and making them ready to interact with other processes. That points to getting the complete quality value chain right and digitalised. This lays the foundation for an integrated Control Strategy, which is a critical part of digital transformation as defined by ICH guidelines and adapted into Pharma 4.0 recommendations.
Some core foundational systems are:
• ERP for Material, vendor and Production planning
• Lab Information Management (LIMS)
• Digital Quality Management Systems (QMS)
• Electronic Batch Records (EBR) and Manufacturing Execution Systems (MES)
• Basic data archival and warehouse systems
• Equipment and process monitoring
PQR and control strategy
• Cloud Platforms to support scalable digital architecture
• Cybersecurity frameworks to ensure GMP-compliant digital environments are safeguarded
These are the building blocks that enable a holistic approach to quality management automation, heading toward predictive quality, real-time release, and seamless data flow.
3. Pharma 4.0 is often perceived as a western-driven initiative. How do you see it evolving uniquely in the Indian pharmaceutical context, especially considering local regulatory dynamics and infrastructure constraints?
Pharma 4.0 is a very good initiative and is indeed rooted in western regulatory thinking like the FDA’s CSA, EMA’s Annex 11, it is a collaborative approach, with foundations in EU and USA. But, its adoption in India must reflect our unique i regulatory expectations, like assured quality and on time supplies and local nuances too.
India is a global pharmaceutical hub, especially in generics and vaccines. Yet, many compliance risks stem from human errors—still the largest contributor to non-compliance. Automation and digitalisation are key to reducing these risks.
However, India’s journey faces unique challenges:
• Resource constraints in Tier-2 and Tier-3 manufacturing units
• Variable infrastructure maturity (power, internet, plant automation)
• Local regulatory focus (CDSCO’s recent guidance is still paper-centric)
That said, India also has an opportunity to leapfrog legacy systems by adopting cloud-native, mobile-first, and AI-powered solutions.
4. In your experience, what are the most significant roadblocks - cultural, operational, or technical - hindering Pharma 4.0 implementation in India?
A primary challenge is the perception that digital transformation is merely an IT initiative rather than a business transformation initiative. This misconception limits both ROI realisation and cross-functional alignment.
Apart from an obvious barrier that is thinking in isolation, which enables process workflow automation, but does not transform the way it works; other key barriers include:
• Cultural: Resistance to change, fear of automation, lack of digital mindset, although this is gradually changing for good.
• Operational: Fragmented legacy systems, siloed data, non-standardised processes, heterogeneous systems issues in integration or information exchange.
• Technical: Low automation baseline, limited in-house digital expertise, lack of scalable IT infrastructure.
Change is underway, but success depends on moving from isolated digital efforts to integrated, cross-functional transformation programs.
5. What role does leadership commitment play in accelerating digital transformation, and how can companies instill a Pharma 4.0 mindset across all organisational levels?
Leadership commitment is non-negotiable. It sets the tone for everything—from vision to execution. Effective transformation requires:
• Clear vision-setting and resource commitment from the C-suite
• Embedding a quality-first culture
• Cross-functional governance that aligns Quality, IT, and Manufacturing
• Organisation-wide upskilling and digital literacy programs
• Celebrating quick wins and internal storytelling to build momentum
Some of the companies that align digital KPIs into business outcomes (e.g., quality lead time, batch release efficiency) tend to see progress faster. In India for the last few years, leadership is increasingly showing intent and constantly pushing for digital transformation, this is significant for scaling up Pharma 4.0 practices.
6. Can you share a success story or case study where a company has effectively integrated Pharma 4.0 principles to transform their manufacturing operations?
As mentioned earlier, a good number of pharma companies in India are in the path of digitalisation. There are two noteworthy initiatives by companies like Cipla and Dr. Reddy's. Their facilities have been recognised as part of the World Economic Forum’s Global Lighthouse network, an acknowledgement for their adoption of Fourth Industrial Revolution technologies in their manufacturing processes.
Cipla’s Indore plant reported a 23% rise in productivity and a 28% reduction in greenhouse gas emissions. Dr. Reddy’s Hyderabad facility achieved similar gains in efficiency and sustainability. What’s striking is their strategic use of technologies like big data, AI, and automation—not in isolation, but as enablers of systemic transformation.
These successes underscore that Pharma 4.0 isn’t a futuristic concept, it’s being lived today
These initiatives resulted in faster batch release times, reduced manual errors, and improved audit readiness.
7. As automation and AI take center stage, how can Pharma 4.0 balance the need for workforce upskilling with the risks of job displacement in the industry?
Pharma 4.0 should be positioned as a human augmentation initiative, not a replacement strategy. Companies should proactively:
• Offer reskilling in data interpretation, digital validation, and system integration
• Design career mobility programs from manual QA roles to digital QMS analysts
• Partner with academia and ed-techs to build modular, pharma-specific curricula
• Establish Centers of Excellence (CoEs) for in-house training
In regulated environments, Human-in-the-loop models, will remain crucial.
8. How do you envision the convergence of cloud computing, IoT, and advanced analytics reshaping Quality Management Systems under Pharma 4.0?
The convergence of Cloud + IoT + Advanced Analytics is transforming QMS by:
• Enabling real-time quality monitoring and riskbased review
• Automating CAPA initiation and tracking using data triggers
• Predicting equipment and process deviations before they occur
• Enhancing audit trails and traceability using blockchain or immutable logs
Together, these capabilities move us from reactive compliance to proactive quality assurance. A data-driven QMS becomes the central nervous system of the digital factory.
9. As Chair of the ISPE Pharma 4.0 CoP, what key initiatives are you planning to promote knowledge sharing and collaboration around Pharma 4.0 in India?
Our focus is on building a community of collaboration, learning, and co-creation. Key initiatives as planned by the Executive leadership of COP India include:
• Industry Roundtables and Knowledge Exchanges with regulators and leading firms
• Maturity Benchmarking Surveys for Indian pharma plants
• Webinars and Workshops on Data Integrity by Design, Digital Validation, and Plug-and- Produce concepts
• Cross-industry CoP chapters to bring together manufacturers, tech providers, and academia
• Promoting India-centric use cases and scalable frameworks for SMEs
• Annual conference of Pharma 4.0 COP along with ISPE India Annual conference.
Our goal is to build a shared vocabulary, practical frameworks, and an enabling ecosystem for digital transformation in Indian pharma
10. From a regulatory standpoint, how receptive are Indian and international agencies to digital-first approaches, and what trends are emerging in compliance automation?
International regulators (FDA, EMA) are increasingly promoting digital-first approaches through initiatives like CSA, eMDR, AI/ML guidance, control strategies like CPV. Especially, COVID- 19, further highlighted the importance of digitalisation, in ensuring business continuity and remote audit readiness.
Subsequently, regulatory agencies quite often recommending digital-first approach, to ensure quality consistency, thereby assurance of supply commitments. In India, CDSCO is upskilling their inspectors and other senior leadership in advanced technologies, so that they are well equipped to audit facility operations.
I had the opportunity of being a trainer in couple of their skill upgrade programs. We discussed interesting topics like global outlook of regulators on technology, new technologies like AI, RPA, digital transformation. Though all these are at an early stage, recent discussions point to openness toward new technologies, which is very encouraging.
Global harmonisation in the regulatory landscape, is also likely to influence Indian policies soon. Indian regulators are actively participating in global summits as well as facilitating them.
Emerging compliance trends include:
• Paperless laboratories, to address data integrity issues
• Electronic logbooks and EBRs, for compliance and analytics
• Digital validation lifecycle tools, for compliance and efficiency
• AI-enabled audit trail review, compliance and efficiency
• Continuous compliance frameworks using real-time monitoring
• Digital control strategies through data science for CPV and other trends
The direction is clear: digital tools are becoming central to sustained compliance.
11. Looking ahead, what does the “future-ready pharma factory” look like in 2030, and what strategic decisions should Indian pharma leaders make today to get there?
The 2030 factory will be:
• Autonomous but supervised: Self-optimising with human oversight
• Data-rich and insight-driven: Continuous process verification through AI
• Digitally validated: Automated change control and traceability
• Interoperable: Modular systems with plug-andplay capability
• Sustainable: Energy-optimised and paperless
• Connected workers, driven by AI for operational efficiency
• Highly enabled data analytics on every process for continuous improvement.
To get there, Indian leaders must:
• Commit to long-term digital maturity roadmaps
• Align IT-OT-Quality under a unified governance model
• Invest in talent, infrastructure, and regulatory alignment
• Treat digital transformation as a business model reinvention, not just technology adoption
Pharma 4.0 has very well laid out guidance documents on each of these topics, it would make planning easy and pave pathways to reimagine pharma manufacturing not just for efficiency, but for resilience and future-readiness.
Author Bio
Sekhar is the Founder of Caliber Technologies, a global leading IT solution provider for regulated industries. He is also the Chair of the ISPE Pharma 4.0 COP India and serves as a Director on the board of ISPE India. Sekhar’s passion is to create simple solutions for complex problems. This has been his driving force behind envisioning a pathdefining Integrated Quality Management model with Caliber’s product suite.
